Active — Not RecruitingNot Applicable

NMBA Reversal and Postoperative Urinary Retention

United States70,000 participantsStarted 2025-06-08

Plain-language summary

In this single-center retrospective cohort study of adult patients who underwent surgery under general anesthesia at Beth Israel Deaconess Medical Center between September 2016 and January 2024, the association between the choice of neuromuscular blocking agent (NMBA) reversal strategy, comparing sugammadex with neostigmine (combined with a muscarinic antagonist), and postoperative urinary retention (POUR) will be evaluated. In secondary analyses, the effects of NMBA reversal strategy and POUR on costs of care and unplanned hospital visits will be analyzed.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients * Non-urinary system surgery * General anesthesia * Use of rocuronium or vecuronium for neuromuscular blockade * Neuromuscular blockade reversal with sugammadex or neostigmine (with atropine and/or glycopyrrolate) * Postoperative admission to the post-anesthesia care unit (PACU) Exclusion Criteria: * American Society of Anesthesiologists (ASA) physical status ≥ V * Emergency reversal with sugammadex (≥ 16 mg/kg of sugammadex) * Presence of foley or suprapubic catheter before or after the procedure * Prior history of bladder resection surgery * Observations with missing data for pre-specified confounding variables

What they're measuring

PACU discharge delay due to POUR

Timeframe: During the admission to the PACU (Perioperative, up to day 1)

Trial details

NCT IDNCT06948409

SponsorBeth Israel Deaconess Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-08-31

View on ClinicalTrials.gov More Neuromuscular Blocking Agents trials